journal article·2025-05Open access

Mitigating Doxorubicin‐Induced Cardiotoxicity and Enhancing Anti‐Tumor Efficacy with a Metformin‐Integrated Self‐Assembled Nanomedicine

Jiaxin Huang, Jieru Yang, Yuanying Yang, Xiaofeng Lu, Juan Xu, Shan Lu, Hong Pan, Wenhu Zhou, Wenqun Li, Songwen Chen

Advanced Science· Volume 12· Issue 17

Abstract

Abstract Doxorubicin (Dox) is a potent chemotherapeutic agent commonly used in cancer treatment. However, cardiotoxicity severely limited its clinical application. To address this challenge, a novel self‐assembled nanomedicine platform, PMDDH, is developed for the co‐delivery of Dox and metformin, an antidiabetic drug with cardioprotective and anti‐tumor properties. PMDDH integrates metformin into a polyethyleneimine‐based bioactive excipient (PMet), with Dox intercalated into double‐stranded DNA and a hyaluronic acid (HA) coating to enhance tumor targeting. The PMDDH significantly improves the pharmacokinetics and tumor‐targeting capabilities of Dox, while metformin enhances the drug's anti‐tumor activity by downregulating programmed cell death ligand 1 (PD‐L1) and activating the AMP‐activated protein kinase (AMPK) signaling pathway. Additionally, the DNA component stimulates the cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING) pathway, which synergizes with Dox‐induced immunogenic cell death (ICD) to promote a robust anti‐tumor immune response. PMDDH markedly reduces Dox‐induced cardiotoxicity by preserving mitochondrial function, reducing reactive oxygen species (ROS) production, and inducing protective autophagy in cardiomyocytes. These findings position PMDDH as a promising dual‐function nanomedicine that enhances the anti‐tumor efficacy of Dox while minimizing its systemic toxicity, offering a safer and more effective alternative for cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Peptidase Inhibition and Analysis · MXene and MAX Phase Materials · Chemotherapy-induced cardiotoxicity and mitigation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy Second Xiangya Hospital Central South University Changsha Hunan 410011 China

Xiangya School of Pharmaceutical Sciences Central South University Changsha Hunan 410013 China

Department of Cardiology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine No.100, Haining Rd Shanghai 200080 China

Department of Cardiology Shanghai General Hospital Jiuquan Hospital No. 22, West St Jiuquan Gansu 735000 China

Hunan Key Laboratory of The Research and Development of Novel Pharmaceutical Preparations School of Pharmaceutical Science Changsha Medical University Changsha Hunan 410219 China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for Central Universities of the Central South University · Hunan Provincial Innovation Foundation for Postgraduate

References (40)

Show source-provided references
1. 10.1038/s43018-021-00304-710.1038/s43018-021-00304-7 ↗
2. 10.1016/S0140-6736(23)00094-610.1016/S0140-6736(23)00094-6 ↗
3. 10.1038/s41467-022-33598-x10.1038/s41467-022-33598-x ↗
4. 10.1200/JCO.22.0190010.1200/JCO.22.01900 ↗
5. 10.1016/j.mam.2023.10120510.1016/j.mam.2023.101205 ↗
6. 10.1161/CIRCULATIONAHA.114.01377710.1161/CIRCULATIONAHA.114.013777 ↗
7. 10.1016/j.actbio.2023.11.00610.1016/j.actbio.2023.11.006 ↗
8. 10.1002/adma.20221026710.1002/adma.202210267 ↗
9. 10.1016/S2352-3026(24)00171-610.1016/S2352-3026(24)00171-6 ↗
10. 10.1038/s41598-024-65508-010.1038/s41598-024-65508-0 ↗
11. 10.1084/jem.2005091510.1084/jem.20050915 ↗
12. 10.1021/acsnano.0c0070810.1021/acsnano.0c00708 ↗
13. 10.1038/s41565-020-00793-010.1038/s41565-020-00793-0 ↗
14. 10.1002/adhm.20230447610.1002/adhm.202304476 ↗
15. 10.1126/sciadv.adk244410.1126/sciadv.adk2444 ↗
16. 10.1002/adma.20231029810.1002/adma.202310298 ↗
17. 10.1021/acsnano.3c0528810.1021/acsnano.3c05288 ↗
18. 10.1001/jamanetworkopen.2023.5106210.1001/jamanetworkopen.2023.51062 ↗
19. 10.1159/00050119510.1159/000501195 ↗
20. 10.1016/j.lfs.2020.11749810.1016/j.lfs.2020.117498 ↗
21. 10.3389/fphar.2024.143586610.3389/fphar.2024.1435866 ↗
22. 10.1038/s41598-023-40061-410.1038/s41598-023-40061-4 ↗
23. 10.3390/ijms22181002710.3390/ijms221810027 ↗
24. 10.1016/j.molcel.2018.07.03010.1016/j.molcel.2018.07.030 ↗
25. 10.1038/ncomms1182210.1038/ncomms11822 ↗
26. 10.1016/j.biomaterials.2022.12153210.1016/j.biomaterials.2022.121532 ↗
27. 10.1016/j.jconrel.2022.05.05610.1016/j.jconrel.2022.05.056 ↗
28. 10.1016/j.bioactmat.2023.05.01610.1016/j.bioactmat.2023.05.016 ↗
29. 10.1038/nrc338010.1038/nrc3380 ↗
30. 10.21147/j.issn.1000-9604.2023.01.0410.21147/j.issn.1000-9604.2023.01.04 ↗
31. 10.1038/s43018-022-00468-w10.1038/s43018-022-00468-w ↗
32. 10.1038/s41577-021-00524-z10.1038/s41577-021-00524-z ↗
33. 10.1136/jitc-2019-00028210.1136/jitc-2019-000282 ↗
34. 10.1128/mBio.00368-1710.1128/mBio.00368-17 ↗
35. 10.3390/ijms2201017310.3390/ijms22010173 ↗
36. 10.1186/s12943-017-0648-110.1186/s12943-017-0648-1 ↗
37. 10.1186/s12967-023-04715-110.1186/s12967-023-04715-1 ↗
38. 10.1016/j.biopha.2023.11469110.1016/j.biopha.2023.114691 ↗
39. 10.1038/ncb215210.1038/ncb2152 ↗
40. Burgoyne J. R. · Autophagy · 2018 · 14 · 1092